arrow
J

Jonathan A. Gutman

university of colorado school of medicine
H指数:39
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia

一项CC-486和Venetoclax口服方案在急性髓系白血病中的I/1b期研究

2026-07-280
OA
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

新诊断急性髓系白血病患者的耐受性与结局:接受连续28天周期性Venetoclax治疗的研究

2026-02-130
PRE
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

奥马曲拉和氮杂胞苷用于初治的伴有过多 blasts 的骨髓增生异常综合征患者的 I/II 期临床试验

2025-10-100
OAAI
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

已知预后模型无法预测Venetoclax和Azacitidine在复发/难治性急性髓系白血病中的结局:一项单中心回顾性分析

2025-08-140
PREAI
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders

成功产生完全人的第二代anti-CD19 CAR T细胞,用于各种自身免疫性疾病患者的临床

2025-02-012
OAAI
Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

奥马扎克汀和阿扎胞苷用于新诊断的伴有过多原始细胞的骨髓增生异常综合征患者

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

比较清髓性预处理与基于全身照射的方案与基于化疗的方案在成年接受脐带血干细胞移植治疗Ph阴性急性淋巴细胞白血病患者中的对比

BLOOD
IF23.1
2024-11-050
PRE
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine

通过数字聚合酶链反应评估的多基因可测量的残留疾病在接受维奈托克/阿扎胞苷的急性髓性白血病患者中具有临床和生物学效用

2023-12-143
OAAI
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
2023-04-1311
OAAI
Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines
2023-02-013
OA
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax plus Azacitidine Versus Intensive Chemotherapy

接受维奈托克联合阿扎胞苷与强化化疗的新诊断急性髓系白血病患者异基因造血干细胞移植后的结果相似

2022-10-0117
OAAI
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents
2020-12-300
OAAI